Table 2.
Changes in PaO2/FiO2 ratio and lung damage evaluated by chest CT (%) in Cohort 1 (a) and Cohort 2 (b) during the same time period before treatment with canakinumab and at 7–10 days after the second administration of canakinumab. (c) Comparison between the changes measured between before the first administration of canakinumab and at follow-up between the two cohorts with regards to the PaO2/FiO2 ratio and lung damage on chest CT scan (%).
| a) Cohort 1 | |||
|---|---|---|---|
| Cohort 1 | Before first administration | At follow-up | P-value |
| (n = 33 at baseline) | |||
| PaO2:FiO2 ratio | |||
| Mean (min–max) | 142.2 (59.0) | 257.4 (105.8) | <0.001 |
| Lung damage (%) | |||
| Mean (SD) | 48.5 (21.1) | 38.6 (18.5) | 0.01 |
| b) Cohort 2 | |||
|---|---|---|---|
| Cohort 2 | Before first administration | At follow-up | P-value |
| (n = 15 at baseline) | |||
| PaO2:FiO2 ratio | |||
| Mean (SD) | 148.1 (58.4) | 197.1 (46.8) | 0.05 |
| Lung damage (%) | |||
| Mean (SD) | 37.9 (15.4) | 35.7 (10.0) | 0.68 |
| c) Comparison between the changes measured between before the first administration of canakinumab and at follow-up between the two cohorts with regards to the PaO2/FiO2 ratio and lung damage on chest CT scan (%). | |||
|---|---|---|---|
| Variable | Cohort 1 | Cohort 2 | P-value |
| Change in PaO2:FiO2 ratio | |||
| Mean (SD) | 99.9 (62.2) | 50.5 (63.3) | 0.03 |
| Change in lung damage (%) | |||
| Mean (SD) | −17.1% (31.1%)a | 11.7% (58.3%) | 0.03 |
a
Matched-pair analysis was available for 23 patients.